Alys Pharmaceuticals chair Francesco De Rubertis (L) and COO Thibaud Portal

Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Eu­ro­pean biotech in­vestor Medicxi is bring­ing six star­tups un­der one roof to form an im­muno-der­ma­tol­ogy drug­mak­er with 14 pipeline projects in a move rem­i­nis­cent of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.